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Background: The aims of this study were to determine prevalence, risk factors and treatment of constipation in patients with Cystic Fibrosis (CF),
as well as the diagnostic value of abdominal radiography.
Methods: A cohort of 214 pediatric CF patients was investigated. Furthermore, 106 abdominal radiographs of CF patients with or without
constipation were independently assessed by three observers on two separate occasions using the Barr and Leech scores.
Results: The prevalence of constipation was 47%. Low total fat absorption and meconium ileus were independent risk factors for constipation in
CF, while fiber and fluid intake were not associated. In CF patients the inter and intraobserver variabilities of the Barr and Leech scores were poor
to moderate.
Conclusion: Constipation is a significant medical issue in CF and was associated with low total fat absorption and a history of meconium ileus.
Finally, abdominal radiography seems of little value in the regular follow-up of CF patients.
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Constipation is one of the gastrointestinal manifestations
of Cystic Fibrosis (CF). It is characterized by a reduced stool
frequency and increased consistency, usually in combination with
abdominal pain and distension and generally responds well to
conservative medical treatment [1,2]. The frequency of this
condition in CF is unclear. The only study addressing this problem
so far reported a prevalence of 26% in patients aged 0–20 years [2].
The main etiological factor for constipation in CF patients
seems to be an altered intestinal fluid composition, caused by a☆ The article was presented at the 31st European Cystic Fibrosis Conference,
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doi:10.1016/j.jcf.2009.11.003defective expression of the Cystic Fibrosis transmembrane
regulator (CFTR) protein in the gut [3,4]. In addition it is
generally thought that a more aggressive treatment with pancreas
supplements would result in more compact feces leading to fecal
impaction [5,6], although no correlation between pancreas
supplement dose and constipation was found [7].
Key elements in the diagnosis of constipation are a careful
medical history and physical examination. In addition abdominal
radiography is frequently performed when constipation is
suspected. In this respect several scoring systems, like the Barr
[8] and the Leech [9] scores, are available to assess the severity of
fecal impaction. However the diagnostic value of these scores has
only been investigated in patients with functional constipation,
but not in CF.
Recently the ESPGHAN CF Working Group made a strict
distinction between the (sub)acute complete ileocecal obstruction,
as seen in the distal intestinal obstruction syndrome (DIOS) and
the gradual fecal impaction of the total colon in constipation [1].d by Elsevier B.V. All rights reserved.
60 H.P.J. van der Doef et al. / Journal of Cystic Fibrosis 9 (2010) 59–63DIOS patients are treated generally successfully with intensive
laxative treatment (meglumine diatrizoate enema, polyethylene
glycol lavage, oral laxatives or an enema) [1]. It seems logical that
in constipated CF patients generally a milder laxative regime will
be used, but no such data are available at present.
The aims of this study were therefore to determine the
prevalence of constipation, its risk factors and diagnostic value
of abdominal radiography in patients with CF. In addition we
listed laxative treatment used.
2. Methods
2.1. Prevalence and risk factors
A retrospective cohort study of all pediatric CF patients (age
≤18 years) under treatment at the University Medical Center
Utrecht, The Netherlands on January 1st, 2006 was performed
according to the guidelines of the medical ethics board of the
University Medical Center Utrecht, The Netherlands.
For constipation and DIOS the recently published definitions
of the ESPGHANCFWorkingGroupwere used [1]. Constipation
was defined as [1] abdominal pain and/or distension or [2a] a
reduced frequency of bowelmovements in the last fewweeks and/
or [2b] increased consistency of stools in the last fewweeks, while
[3] the symptoms are relieved by the use of laxatives. DIOS was
defined as the combination of [1] complete intestinal obstruction,
as evidenced by vomiting of bilious material and/or fluid levels in
small intestine on an abdominal radiograph with [2] a fecal mass in
ileocecum and [3] abdominal pain and/or distension. Incomplete
or impending DIOS was defined as (1) a short history (days) of
abdominal pain or distension or both and (2) a fecal mass in
ileocecum, but without signs of complete obstruction.
Three-day dietary records (3 consecutive days including 1
weekend day) were completed by patient and/or family every
year and analyzed by a registered dietitian (J.W.). The dietary
data used for analysis were obtained 0 to 6 months before
patients presented for the first time with constipation and were
compared with the last available dietary data obtained in the
patients without constipation or DIOS (complete or incom-
plete). Nutrient intake was expressed as percentage of the
gender- and age-specific Reference Daily Intake (RDI) [10].
Total fat absorption was calculated from the mean daily fat
intake of three-day dietary records and the daily fecal fat output
and was expressed as percentage of the mean daily fat intake.
For the determination of CFTR genotypes only alleles with
known mutations were analyzed. Then the CFTR genotypes of
the CF patients were subdivided into two groups: the first group
consisted of patients with a severe genotype, defined as 2 severe
CFTR mutations (class I–III) and the second group consisted of
patients with a mild genotype, defined as at least 1 mild mutation
(class IV–V) [11]. The distribution of DF508 homozygous
patients was also examined.
2.2. Abdominal radiography
Between April and December 2006 all pediatric CF
patients (age ≤18 years) who visited the outpatient clinicfor the annual checkup in the University Medical Center
Utrecht underwent abdominal radiography regardless of the
presence or absence of abdominal symptoms or constipation.
A retrospective analysis of this group was subsequently
performed according to the guidelines of the medical ethics
board of the University Medical Center Utrecht, The Nether-
lands. Three observers; a medical student (S.F.), an experi-
enced pediatric radiologist (F.B.) and an experienced
pediatric gastroenterologist (F.K.) independently assessed
the abdominal radiographs taken. The three observers were
blinded to the study objective and each abdominal radiograph
was evaluated on two separate occasions, 3 weeks apart. Each
abdominal radiograph was scored according to two different
scoring systems and before the first scoring, the different
systems were not discussed by the observers. The first
method, described by Barr et al. [8], quantifies the amount of
feces in four different bowel segments (ascending colon,
transverse colon, descending colon and rectum) and is scored
respectively from 0 to 2, 0 to 5, 0 to 5 and 0 to 5. Also the
consistency of the feces, i.e. granular or rocky stools is scored
respectively from 0 to 3 and 0 to 5. Constipation is defined as
a score≥10. The second method was described more recently
by Leech et al. [9]. In this system the colon is divided into
three colonic segments (the right colon, the left colon and the
rectosigmoid segment) and the amount of feces in each
segment is scored from 0 to 5. Constipation is defined as a
score ≥9.
The presence of radiological constipation in the first
evaluation of all three observers according to the Barr and
Leech scores were compared with the presence of constipation
according to the ESPGHAN criteria [1] as gold standard and the
sensitivity, specificity, positive and negative predictive values
(PPV and NPV) were calculated. Furthermore, the interob-
server variability of the Barr and Leech scores was calculated
using the first evaluation of the three observers and the
intraobserver variability was calculated using both evaluations
of the observers.
2.3. Statistical analysis
Data were described as mean and standard deviation for
ordinal values, and absolute and relative frequencies for
nominal values. Logistic regression was used to test the effect
of potential risk factors and variables contributing significantly
(pb0.05) were included in the multivariate analysis. Unweight-
ed kappa coefficients were calculated as indicators of inter and
intraobserver variabilities for nominal variables (presence or
absence of radiological constipation) and weighted kappa
coefficients were calculated for ordinal variables (amount of
points scored by the observers). Kappa coefficients b0.20,
0.21–0.40, 0.41–0.60, 0.61–0.80, and 0.81–1.00 were consid-
ered to indicate poor, fair, moderate, good and very good
agreement, respectively [12]. Values were considered signifi-
cant if p≤0.05. The weighted kappa coefficient was calculated
using R software (Free Software Foundation Inc., Boston, MA,
USA), while all other statistical analyses were performed using
SPSS software (SPSS Inc., Chicago, IL, USA).
Table 1
Clinical characteristics associated with constipation in Cystic Fibrosis.
Characteristics All patients Constipation Controls p-value OR (95%CI)
Patient number 214 107 107
Gender (male) 119 (56%) 61 (57%) 58 (54%) 0.68 1.10 (0.65–1.92)
Age diagnosis CF a 1.31 (2.08) 1.12 (1.64) 1.49 (2.43) 0.20 0.92 (0.80–1.05)
Current age a 9.96 (4.64) 10.31 (4.37) 9.60 (4.90) 0.26 1.03 (0.98–1.10)
CFTR genotype
Severe 174 (81%) 93 (87%) 81 (76%) 0.34 b 1.64 (0.60–4.51) b
DF508/DF508 130 (61%) 73 (68%) 57 (53%) 0.25 b 1.83 (0.66–5.11) b
Mild 17 (8%) 7 (7%) 10 (9%)
Clinical manifestations
Pancreas insufficiency 207 (97%) 106 (99%) 101 (94%) 0.091 0.16 (0.019–1.34)
Meconium ileus 19 (9%) 14 (13%) 5 (5%) 0.038 3.07 (1.07–8.86)
Dietary intake
Fiber (% RDI) a 0.58 (0.19) 0.58 (0.23) 0.58 (0.17) 0.93 0.92 (0.14–6.27)
Fluid (% RDI) a 0.87 (0.21) 0.89 (0.21) 0.86 (0.21) 0.46 1.88 (0.35–10.00)
Total fat absorption a 0.89 (0.08) 0.86 (0.09) 0.90 (0.07) 0.012 0.003 (0.00–0.28)
a Mean (SD).
b Severe genotype or DF508 homozygous vs. mild genotype.
Table 2
Sensitivity, specificity and positive and negative predictive values of the
presence of radiological constipation according to the Barr and Leech scores in
children with Cystic Fibrosis.
Radiologist Gastroenterologist Medical student
Barr score
Sensitivity 0.61 0.14 0.53
Specificity 0.43 0.96 0.59
Positive predictive value 0.35 0.63 0.40
Negative predictive value 0.68 0.68 0.71
Leech score
Sensitivity 0.72 0.11 0.50
Specificity 0.34 0.93 0.63
Positive predictive value 0.36 0.44 0.41
Negative predictive value 0.71 0.67 0.71
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3.1. Prevalence and risk factors
The study group consisted of 230 pediatric CF patients (age
≤18 years) under treatment at the University Medical Center
Utrecht, The Netherlands on January 1st, 2006. Within this
study group, 107 patients (47%) had a history of constipation,
while 46 patients (20%) were constipated at January 1st, 2006.
Sixteen patients with a history of DIOS (complete or
incomplete) were excluded in the analysis of risk factors. The
characteristics of the 107 constipation patients were compared
with 107 CF patients without a history of constipation or DIOS
(complete or incomplete) and are reported in Table 1.
Meconium ileus was significantly more frequent in patients
with a history of constipation than in patients without
constipation (13% vs. 5%, p=0.038). In the subgroup of the
19 meconium ileus patients surgical treatment for meconium
ileus was more common in constipation patients than in patients
without constipation (71% vs. 60%), although no statistical
significance was reached (p=1.00). Also pancreatic insufficien-
cy was more common in the constipated group than in control
CF patients (99% vs. 94%), although this difference was not
significant (p=0.091). However total fat absorption was
significantly lower in patients with constipation than in patients
without constipation (0.86±0.09 vs. 0.90±0.07, p=0.012). All
other variables (current age, age at diagnosis of CF, gender,
CFTR genotype, mean fiber intake and mean fluid intake) were
not significantly different between patients with or without
constipation.
Logistic regression analysis showed that meconium ileus at
birth (p=0.024; OR 4.69, 95%CI 1.22–18.0) and low total fat
absorption (p=0.010; OR 0.002, 95%CI 0.000–0.24) were
indeed both independently associated with constipation.3.2. Abdominal radiography
Abdominal radiography was performed in the 106 CF
patients who visited the outpatient clinic for the annual checkup
in the University Medical Center Utrecht, The Netherlands
betweenApril andDecember 2006. Of the 106 patients 36 (34%)
were constipated and 70 (66%) were not constipated according
to the ESPGHAN criteria [1]. With this criterion as a gold
standard sensitivity, specificity, PPV and NPV of radiological
constipation according to the different scoring systems generally
was low (Table 2). For the Barr score the observers reported
sensitivities ranging from 0.14 to 0.61, specificities ranging from
0.43 to 0.96, PPV ranging from 0.35 to 0.63 and NPV ranging
from 0.68 to 0.71. For the Leech score the observers report
sensitivities ranging from 0.11 to 0.72, specificities ranging from
0.34 to 0.93, PPV ranging from 0.36 to 0.44 and NPV ranging
from 0.67 to 0.71.
62 H.P.J. van der Doef et al. / Journal of Cystic Fibrosis 9 (2010) 59–63Furthermore, the inter and intraobserver variabilities of the
three observers according to the two different scoring systems
generally were low too. The inter and intraobserver variabilities
of the Barr and Leech scores for the presence of radiological
constipation (Barr score b10 vs. ≥10 and Leech score b9 vs.
≥9) ranged from an unweighted kappa coefficient of 0.08
(poor) to 0.44 (moderate) and the inter and intraobserver
variabilities of the Barr and Leech scores for the amount of
points scored ranged from a weighted kappa coefficient of 0.09
(poor) to 0.55 (moderate).
3.3. Treatment of constipation patients
In our patient group 58% had had at least 1 oral laxative
(OL), 26% 2 OL, 8% 3 OL, 6% 4 OL and 2% 5 OL. Generally
patients started with lactulose or polyethylene glycol. If the
effect was insufficient one or two additional OLs were added. In
53 patients (50%) at least once an enema was necessary and in
14 patients (13%) intestinal lavage. Eight patients received a
stimulant laxative for a short period.
4. Discussion
In this study we determined the prevalence, risk factors and
treatment of constipation in a cohort of CF patients, as well as
the diagnostic value of abdominal radiography in this condition.
One hundred and seven out of 230 patients (47%) had a
history of constipation, while 46 out of 230 patients (20%) were
constipated at January 1st, 2006. Prevalence numbers of
constipation in CF are scarce; only one study published in
1986 has reported prevalence numbers of constipation in CF
[2]. This study observed that constipation had been present in
26% of all CF patients aged 0–20 years [2], which is
significantly lower than prevalence in the present study
(pb0.001). While it is possible that the prevalence of
constipation has increased over time, it is as likely that laxatives
are prescribed more easily nowadays in CF patients suspected
of constipation, especially as current laxatives are almost devoid
of side effects. As both in our definition for constipation and in
the definition of Rubinstein et al. [2] the use of laxatives is a key
component, such a change in practice might result in the
increasing prevalence numbers we here describe.
In the current study we found that meconium ileus was
independently associated with constipation. An association
between meconium ileus and DIOS has been reported
previously [13]. It seems indeed logical that both meconium
ileus, DIOS and constipation in CF are an interrelated group of
manifestations, ranging from severe to mild intestinal obstruc-
tion and sharing a common pathophysiology.
The relationship between pancreatic insufficiency or poorly
controlled steatorrhea and constipation is unclear and
conflicting results have been published. In general, it is thought
that constipation is correlated with highly dosed pancreatic
supplements [5,6]. However this is not supported by Baker et al.
[7], who report no correlation between constipation and the
dosage of pancreatic supplements. We now found that
constipation patients have a lower total fat absorption thancontrol patients, although both patient groups (with and without
constipation) had an adequate control of steatorrhea with a mean
total fat absorption of 86% and 90% respectively [14]. Slow
intestinal transit and malabsorption may allow undigested food
to enter the colon over a prolonged period [15,16]. This could
lead, in combination with impaired intestinal secretion [3,4], to
sticky intestinal mucus and constipation.
Finally, in concordance with a report describing Belgian CF
patients [17], fiber intake was not correlated with constipation
in CF. Furthermore, no differences in the fluid intake between
patients with or without constipation were found, despite the
general opinion that inadequate fluid intake is an etiological
factor of constipation in CF [2].
In children with CF the Barr and Leech scores have poor
sensitivity, specificity, PPV and NPV for diagnosing constipa-
tion, with a considerable overlap in Barr and Leech scores
between constipated and nonconstipated patients. In addition,
poor inter and intraobserver variabilities were found when
scoring abdominal radiographs in CF patients. Similar results
have been published in patients with functional constipation; a
systematic review showed a low diagnostic value of abdominal
radiography (sensitivity 60–80% and specificity 35–90%) [18],
while the inter and intraobserver variabilities of the different
scoring systems are poor too [19,20]. Consequently, abdominal
radiography is not recommended as a standard diagnostic tool in
the regular gastrointestinal follow-up of CF patients. However,
abdominal radiography is useful to differentiate between
constipation and the distal intestinal obstruction syndrome in
CF patients with acute abdominal pain [1].
Currently, polyethylene glycol seems to be the preferred
initial treatment for both constipation and DIOS (complete and
incomplete), because it is as effective and does not have the side
effects that are inherent to lactulose (flatulence and abdominal
cramps) [21].
In conclusion, constipation is a significant medical issue in
CF patients, with a prevalence of 47%. Furthermore, we found
that low total fat absorption and meconium ileus were
independent risk factors for constipation in CF, while fiber
and fluid intake were not associated with constipation in CF. In
addition, the diagnostic value of abdominal radiography in CF
is limited. Abdominal radiography is therefore not recom-
mended in the regular follow-up of CF patients.
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